Cancer Letters
Volume 224, Issue 1 , Pages 81-91 , 16 June 2005

P2Y purinergic receptors regulate the growth of human melanomas

  • Nicholas White

      Affiliations

    • Autonomic Neuroscience Institute, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK
    • Department of Plastic and Reconstructive Surgery, Royal Free Hospital, Pond Street, London NW3 2QG, UK
    • ,
  • Mina Ryten

      Affiliations

    • Autonomic Neuroscience Institute, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK
    • ,
  • Elizabeth Clayton

      Affiliations

    • RAFT Institute of Plastic Surgery, Mount Vernon Hospital, Northwood, Middlesex HA6 2RN, UK
    • ,
  • Peter Butler

      Affiliations

    • Department of Plastic and Reconstructive Surgery, Royal Free Hospital, Pond Street, London NW3 2QG, UK
    • ,
  • Geoffrey Burnstock

      Affiliations

    • Autonomic Neuroscience Institute, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 207 8302948; fax: +44 207 8302949.

Received 3 October 2004 ,Revised 6 November 2004 ,Accepted 9 November 2004.

References 

  1. Dreiling L, Hoffman S, Robinson WA. Melanoma: epidemiology, pathogenesis, and new modes of treatment. Adv. Intern. Med. 1996;41:553–604
  2. Osborne JE. Skin cancer screening and surveillance. Br. J. Dermatol. 2002;146:745–754
  3. Serrone L, Hersey P. The chemoresistance of human malignant melanoma: an update. Melanoma Res. 1999;9:51–58
  4. Burnstock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler. Thromb. Vasc. Biol. 2002;22:364–373
  5. Greig AV, Linge C, Terenghi G, McGrouther DA, Burnstock G. Purinergic receptors are part of a functional signaling system for proliferation and differentiation of human epidermal keratinocytes. J. Invest. Dermatol. 2003;120:1007–1015
  6. Burnstock G. A basis for distinguishing two types of purinergic receptor. In:  Straub RW,  Bolis L editor. Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach. New York: Raven Press; 1978;p. 107–118
  7. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 2001;53:527–552
  8. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol. Rev. 1998;50:413–492
  9. Abbracchio MP, Burnstock G. Purinoceptors: are there families of P2X and P2Y purinoceptors?. Pharmacol. Ther. 1994;64:445–475
  10. Burnstock G, Kennedy C. Is there a basis for distinguishing two types of P2-purinoceptor?. Gen. Pharmacol. 1985;16:433–440
  11. Khakh BS, Barnard EA, Burnstock G, Kennedy C, King BF, North RA, et al. P2X receptor-channels. In:  Girdlestone D editors. The IUPHAR Compendium Of Receptor Characterization and Classification. London: IUPHAR Media Ltd; 2000;p. 290–305
  12. King BF, Burnstock G, Boyer JL, Boeynaems J-M, Weisman GA, Kennedy C, et al. The P2Y receptors. In:  Girdlestone D editors. The IUPHAR Compendium of Receptor Characterization and Classification. London: IUPHAR Media Ltd; 2000;p. 306–320
  13. Berridge MJ. Inositol trisphosphate as a second messenger in signal transduction. Ann. N.Y. Acad. Sci. 1987;494:39–51
  14. Berridge MJ. Capacitative calcium entry. Biochem. J. 1995;312(Pt 1):1–11
  15. Hoebertz A, Arnett TR, Burnstock G. Regulation of bone resorption and formation by purines and pyrimidines. Trends Pharmacol. Sci. 2003;24:290–297
  16. Roman RM, Fitz JG. Emerging roles of purinergic signaling in gastrointestinal epithelial secretion and hepatobiliary function. Gastroenterology. 1999;116:964–979
  17. Rapaport E. Treatment of human tumor cells with ADP or ATP yields arrest of growth in the S phase of the cell cycle. J. Cell. Physiol. 1983;114:279–283
  18. Rapaport E, Fontaine J. Generation of extracellular ATP in blood and its mediated inhibition of host weight loss in tumor-bearing mice. Biochem. Pharmacol. 1989;38:4261–4266
  19. Maaser K, Hopfner M, Kap H, Sutter AP, Barthel B, von Lampe B, et al. Extracellular nucleotides inhibit growth of human oesophageal cancer cells via P2Y(2)-receptors. Br. J. Cancer. 2002;86:636–644
  20. Janssens R, Boeynaems JM. Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells. Br. J. Pharmacol. 2001;132:536–546
  21. Schafer R, Sedehizade F, Welte T, Reiser G. ATP- and UTP-activated P2Y receptors differently regulate proliferation of human lung epithelial tumor cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2003;285:L376–L385
  22. Nylund G, Nordgren S, Delbro DS. Expression of P2Y2 purinoceptors in MCG 101 murine sarcoma cells, and HT-29 human colon carcinoma cells. Auton. Neurosci. 2004;112:69–79
  23. Merighi S, Varani K, Gessi S, Cattabriga E, Iannotta V, Ulouglu C, et al. Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. Br. J. Pharmacol. 2001;134:1215–1226
  24. Merighi S, Mirandola P, Milani D, Varani K, Gessi S, Klotz KN, et al. Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J. Invest. Dermatol. 2002;119:923–933
  25. Slater M, Scolyer RA, Gidley-Baird A, Thompson JF, Barden JA. Increased expression of apoptotic markers in melanoma. Melanoma Res. 2003;13:137–145
  26. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J. Natl Cancer Inst. 1973;51:1417–1423
  27. Adrian K, Bernhard MK, Breitinger HG, Ogilvie A. Expression of purinergic receptors (ionotropic P2X1-7 and metabotropic P2Y1-11) during myeloid differentiation of HL60 cells. Biochim. Biophys. Acta. 2000;1492:127–138
  28. Gillies RJ, Didier N, Denton M. Determination of cell number in monolayer cultures. Anal. Biochem. 1986;159:109–113
  29. Tulapurkar ME, Laubinger W, Nahum V, Fischer B, Reiser G. Subtype specific internalization of P2Y1 and P2Y2 receptors induced by novel adenosine 5′-O-(1-boranotriphosphate) derivatives. Br. J. Pharmacol. 2004;142:869–878
  30. Moore DJ, Chambers JK, Wahlin JP, Tan KB, Moore GB, Jenkins O, et al. Expression pattern of human P2Y receptor subtypes: a quantitative reverse transcription-polymerase chain reaction study. Biochim. Biophys. Acta. 2001;1521:107–119
  31. Burnstock G. The past, present and future of purine nucleotides as signalling molecules. Neuropharmacology. 1997;36:1127–1139
  32. Abraham EH, Salikhova AY, Rapaport E. ATP in the treatment of advanced cancer. In:  Schwiebert EM editors. Extracellular Nucleotides and Nucleosides. San Diego: Elsevier; 2003;p. 415–452
  33. Dubyak GR, De Young MB. Intracellular Ca2+ mobilization activated by extracellular ATP in Ehrlich ascites tumor cells. J. Biol. Chem. 1985;260:10653–10661
  34. Lin WW, Chuang DM. Extracellular ATP stimulates inositol phospholipid turnover and calcium influx in C6 glioma cells. Neurochem. Res. 1993;18:681–687
  35. Cowen DS, Berger M, Nuttle L, Dubyak GR. Chronic treatment with P2-purinergic receptor agonists induces phenotypic modulation of the HL-60 and U937 human myelogenous leukemia cell lines. J. Leukoc. Biol. 1991;50:109–122
  36. Popper LD, Batra S. Calcium mobilization and cell proliferation activated by extracellular ATP in human ovarian tumour cells. Cell Calcium. 1993;14:209–218
  37. Ryten M, Dunn PM, Neary JT, Burnstock G. ATP regulates the differentiation of mammalian skeletal muscle by activation of a P2X5 receptor on satellite cells. J. Cell. Biol. 2002;158:345–355
  38. Chueh SH, Kao LS. Extracellular ATP stimulates calcium influx in neuroblastoma × glioma hybrid NG108-15 cells. J. Neurochem. 1993;61:1782–1788
  39. Gartland A, Hipskind RA, Gallagher JA, Bowler WB. Expression of a P2X7 receptor by a subpopulation of human osteoblasts. J. Bone Miner. Res. 2001;16:846–856
  40. Greig AV, Linge C, Healy V, Lim P, Clayton E, Rustin MH, et al. Expression of purinergic receptors in non-melanoma skin cancers and their functional roles in A431 cells. J. Invest. Dermatol. 2003;121:315–327
  41. Katzur AC, Koshimizu T, Tomic M, Schultze-Mosgau A, Ortmann O, Stojilkovic SS. Expression and responsiveness of P2Y2 receptors in human endometrial cancer cell lines. J. Clin. Endocrinol. Metab. 1999;84:4085–4091
  42. Hopfner M, Lemmer K, Jansen A, Hanski C, Riecken EO, Gavish M, et al. Expression of functional P2-purinergic receptors in primary cultures of human colorectal carcinoma cells. Biochem. Biophys. Res. Commun. 1998;251:811–817
  43. Sellers LA, Simon J, Lundahl TS, Cousens DJ, Humphrey PP, Barnard EA. Adenosine nucleotides acting at the human P2Y1 receptor stimulate mitogen-activated protein kinases and induce apoptosis. J. Biol. Chem. 2001;276:16379–16390

PII: S0304-3835(04)00884-5

doi: 10.1016/j.canlet.2004.11.027

Cancer Letters
Volume 224, Issue 1 , Pages 81-91 , 16 June 2005

Article Tools

* Image Usage & Resolution